You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

~ Buy the VIZAMYL (flutemetamol f-18) Drug Profile, 2024 PDF Report in the Report Store ~

VIZAMYL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Vizamyl, and what generic alternatives are available?

Vizamyl is a drug marketed by Ge Healthcare and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-four patent family members in twenty-five countries.

The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this compound. Additional details are available on the flutemetamol f-18 profile page.

DrugPatentWatch® Generic Entry Outlook for Vizamyl

Vizamyl was eligible for patent challenges on October 25, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 16, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VIZAMYL?
  • What are the global sales for VIZAMYL?
  • What is Average Wholesale Price for VIZAMYL?
Summary for VIZAMYL
International Patents:84
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 3
Clinical Trials: 6
Patent Applications: 99
Drug Prices: Drug price information for VIZAMYL
What excipients (inactive ingredients) are in VIZAMYL?VIZAMYL excipients list
DailyMed Link:VIZAMYL at DailyMed
Drug patent expirations by year for VIZAMYL
Drug Prices for VIZAMYL

See drug prices for VIZAMYL

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VIZAMYL
Generic Entry Date for VIZAMYL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIZAMYL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Yale UniversityPhase 1
University of UtahPhase 2
University Hospital, ToulouseEarly Phase 1

See all VIZAMYL clinical trials

Pharmacology for VIZAMYL

US Patents and Regulatory Information for VIZAMYL

VIZAMYL is protected by three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIZAMYL is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VIZAMYL

Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: DIAGNOSTIC RADIOIMAGING

Benzothiazole derivative compounds, compositions and uses
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Radiopharmaceutical composition
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIZAMYL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 ⤷  Sign Up ⤷  Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 ⤷  Sign Up ⤷  Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 ⤷  Sign Up ⤷  Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 ⤷  Sign Up ⤷  Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-002 Oct 25, 2013 ⤷  Sign Up ⤷  Sign Up
Ge Healthcare VIZAMYL flutemetamol f-18 INJECTABLE;INTRAVENOUS 203137-001 Oct 25, 2013 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VIZAMYL

When does loss-of-exclusivity occur for VIZAMYL?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 08292201
Patent: Radiopharmaceutical composition
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 0815129
Patent: COMPOSIÇÃO RADIOFARMACÊUTICA, E, MÉTODOS PARA PREPARAÇÃO DE UMA COMPOSIÇÃO RADIOFARMACÊUTICA, E PARA DETERMINAÇÃO DA PRESENÇA, LOCALIZAÇÃO E/OU QUANTIDADE DE UM OU MAIS DEPÓSITOS DE AMILÓIDE EM UM ÓRGÃO OU ÁREA DO CORPO DE UM INDIVÍDUO
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 94084
Patent: COMPOSITION RADIOPHARMACEUTIQUE (RADIOPHARMACEUTICAL COMPOSITION)
Estimated Expiration: ⤷  Sign Up

China

Patent: 1790387
Patent: Radiopharmaceutical composition
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 82988
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 82988
Patent: COMPOSITION RADIOPHARMACEUTIQUE (RADIOPHARMACEUTICAL COMPOSITION)
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 46710
Patent: RADIOPHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 500007
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 3316
Patent: תכשיר רוקחי רדיואקטיבי המכיל תרכובת בנזוטיאזול מסומנת ראדיואקטיבית ונשא כשיר ביולוגית ,שיטה להכנת התכשיר ושיטה לדימות על ידי שימוש בו (Radiopharmaceutical composition comprising isotopically-labeled benzothiazole compound and a biocompatible carrier, a method for preparing the composition and a method of imaging using the same)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 67708
Estimated Expiration: ⤷  Sign Up

Patent: 10536931
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 10002196
Patent: COMPOSICION RADIOFARMACEUTICA. (RADIOPHARMACEUTICAL COMPOSITION.)
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 3616
Patent: RADIOPHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷  Sign Up

Norway

Patent: 15006
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 82988
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 82988
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 75267
Patent: РАДИОФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (RADIOPHARMACEUTICAL COMPOSITION)
Estimated Expiration: ⤷  Sign Up

Patent: 10101935
Patent: РАДИОФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1000718
Patent: Radiopharmaceutical composition
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1571572
Estimated Expiration: ⤷  Sign Up

Patent: 100055440
Patent: RADIOPHARMACEUTICAL COMPOSITION
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 64715
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIZAMYL around the world.

Country Patent Number Title Estimated Expiration
Spain 2393921 ⤷  Sign Up
Portugal 2264018 ⤷  Sign Up
Norway 20054674 ⤷  Sign Up
Israel 203316 תכשיר רוקחי רדיואקטיבי המכיל תרכובת בנזוטיאזול מסומנת ראדיואקטיבית ונשא כשיר ביולוגית ,שיטה להכנת התכשיר ושיטה לדימות על ידי שימוש בו (Radiopharmaceutical composition comprising isotopically-labeled benzothiazole compound and a biocompatible carrier, a method for preparing the composition and a method of imaging using the same) ⤷  Sign Up
Japan 2004506723 ⤷  Sign Up
Russian Federation 2010101935 РАДИОФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ⤷  Sign Up
China 1784392 Benzothiazole derivative compounds,compositions and uses ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VIZAMYL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2182988 573 Finland ⤷  Sign Up
1611115 2015/004 Ireland ⤷  Sign Up PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
2182988 2015006 Norway ⤷  Sign Up PRODUCT NAME: VIZAMYL; REG. NO/DATE: EU/1/14/941 20140822
2182988 15C0006 France ⤷  Sign Up PRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
1611115 122015000016 Germany ⤷  Sign Up PRODUCT NAME: FLUTEMETAMOL (18F) ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ, HYDRAT ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/941 20140822
1611115 CA 2015 00009 Denmark ⤷  Sign Up PRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140822
2182988 CR 2015 00008 Denmark ⤷  Sign Up PRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140826
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.